Landmark Clinical Study on Natural Cancer Treatment. The significance of a dietary supplement being studied in a multi-oncology center clinical trial and published in a major cancer medical journal, represents a landmark breakthrough in integrative cancer research. Final results from the long-term clinical trial are equally impressive.
Published August 2023 in the prestigious journal, Nutrients, this clinical study showed that modified citrus pectin provided significant benefits against prostate cancer progression and PSA doubling time (PSADT) in men with biochemically recurrent prostate cancer (BRPC). With an impact factor of 5.7, Nutrients is an important journal for presenting breakthrough research on nutritional interventions to the broader medical community. Results followed a group of patients with BRPC who had been taking the researched form of MCP for a total of 18 months. MCP was shown in the study to reduce prostate cancer progression, stabilize or decrease PSA, and slow PSA doubling time (PSADT) without hormonal interference or side effects. Initially, the study enrolled 59 prostate cancer patients from leading oncology centers in Israel. Participants took 4.8 grams of MCP 3 times/day. After 6 months, 46 subjects (78%) showed response to MCP, with decreased or stabilized PSA in 34 subjects (58%). 44 subjects (75%) showed improvement of PSADT with negative scans. These early 6-month results were published October 2021 in the journal, Nutrients.(1) For the final arm of the study, 46 of 59 subjects were eligible to continue for an additional 12 months. 7 subjects dropped from the study and purchased MCP independently, with steady benefits. The remaining 39 subjects continued an additional 12 months, for a total of 18 months. Final 18-month results demonstrated that 90% of the subjects had improvement or stabilization of PSADT, 62% had decreased or stable PSA, and 85% had no disease progression, biochemically and in scans. No toxicity or side effects were observed. These results were presented at the American Society of Clinical Oncology Genitourinary Symposium in February 2023, and published September 2023 in Nutrients.(2) Breakthrough Results in Prostate Cancer
This long-term clinical trial is a landmark study because it highlights the robust benefits and safety of a non-hormonal treatment—MCP—in the management of aggressive prostate cancer. Therapeutic options for this patient population are limited, and hormonal interventions carry major risks that can shorten the window of time for treatment viability. This study adds to the evidence of MCP as an effective alternative to high-risk hormonal interventions.
With 80+ published studies, the original and researched form of MCP is becoming one of the most-studied dietary supplements demonstrating clinically relevant benefits for today’s most critical areas of health, including cancer. This groundbreaking study adds to the growing body of data on MCP in areas of oncology, cardiovascular and kidney health, and others.
This information has not been reviewed by the FDA and does not claim to cure, prevent, treat or diagnose any disease
